# Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)

> **NCT00505232** · PHASE2 · COMPLETED · sponsor: **CABYC** · enrollment: 30 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Y-90 Ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00505232
- **Lead sponsor:** CABYC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2010-03
- **Final completion:** 2011-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505232, "Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00505232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*